Vimarsana
Biggest News Aggregation in the World

Page 26 - Ouse Model News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ouse Model. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ouse Model Today - Breaking & Trending Today

Protein heat shock transcription factor 1 may be a viable therapeutic target for hepatoblastoma - Vimarsana News

Protein heat shock transcription factor 1 may be a viable therapeutic target for hepatoblastoma

Although rare compared to adult liver cancers, hepatoblastoma is the most common pediatric liver malignancy, and its incidence is increasing.

Targeting T cell iron metabolism may offer a new approach for treating lupus - Vimarsana News

Targeting T cell iron metabolism may offer a new approach for treating lupus

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) -; the most common form of the chronic autoimmune disease lupus.

CNB-CSIC vaccine fully protects against SARS-CoV-2 infection of the brain - Vimarsana News

CNB-CSIC vaccine fully protects against SARS-CoV-2 infection of the brain

In a recent study published in the journal Nature Neuroscience, researchers in Spain described the effectiveness of a modified vaccinia virus Ankara (MVA) vector severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  vaccine candidate in protecting against SARS-CoV-2 infection in the brain using a mouse model.

Researchers demonstrate how CNB-CSIC vaccine fully protects against SARS-CoV-2 infection of the brain - Vimarsana News

Researchers demonstrate how CNB-CSIC vaccine fully protects against SARS-CoV-2 infection of the brain

Although the pathology of the respiratory system is the main impact of the COVID-19 disease, caused by the SARS-CoV-2 coronavirus, many of the patients manifest important neurological symptoms, such as loss of smell (anosmia), headaches, malaise, cognitive loss, epilepsy, ataxia and encephalopathy, among others.

Pan-vaccine antigen strategy confers protection against cross-clade SARS-CoV-2 variants, including vaccine-resistant Omicron variants - Vimarsana News

Pan-vaccine antigen strategy confers protection against cross-clade SARS-CoV-2 variants, including vaccine-resistant Omicron variants

Researchers developed a novel pan-vaccine antigen (Span)-based subunit vaccine against COVID-19.